Bernhardt Zeiher

3.9k total citations · 1 hit paper
35 papers, 1.7k citations indexed

About

Bernhardt Zeiher is a scholar working on Pulmonary and Respiratory Medicine, Epidemiology and Pharmacology. According to data from OpenAlex, Bernhardt Zeiher has authored 35 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 10 papers in Epidemiology and 7 papers in Pharmacology. Recurrent topics in Bernhardt Zeiher's work include Gastrointestinal motility and disorders (6 papers), Antifungal resistance and susceptibility (6 papers) and Fibromyalgia and Chronic Fatigue Syndrome Research (5 papers). Bernhardt Zeiher is often cited by papers focused on Gastrointestinal motility and disorders (6 papers), Antifungal resistance and susceptibility (6 papers) and Fibromyalgia and Chronic Fatigue Syndrome Research (5 papers). Bernhardt Zeiher collaborates with scholars based in United States, United Kingdom and Japan. Bernhardt Zeiher's co-authors include Michael J. Welsh, Joseph Zabner, John B. Stokes, Fiona J. McDonald, Christopher M. Adams, Alexei Dmitrienko, Margaret P. Price, Kenneth A. Volk, Peter M. Snyder and Antonio Artigas and has published in prestigious journals such as Cell, Journal of Clinical Investigation and SHILAP Revista de lepidopterología.

In The Last Decade

Bernhardt Zeiher

35 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A mouse model for the delta F508 allele of cystic fibrosis.

1995 249 citations Bernhardt Zeiher, E. J. Eichwald et al. Journal of Clinical Investigation profile →

Peers

Bernhardt Zeiher

PRM

EPIDE

IMMUN

GENET

Frances L. Szeto United States

Jeffrey D. Edelson Canada

Hong Ren China

Otwin Linderkamp Germany

Robert D. Bart United States

Ray K. Iles United Kingdom

Clement Ho United States

Qiu Zhao China

Yoshiyuki Watanabe Japan

Hong-Long Ji United States

Frances L. Szeto United States

Bernhardt Zeiher

351 ×0.5

PRM

355 ×0.6

282 ×1.0

EPIDE

188 ×0.8

IMMUN

119 ×0.7

GENET

Citations per year, relative to Bernhardt Zeiher Bernhardt Zeiher (= 1×) peers Frances L. Szeto

Countries citing papers authored by Bernhardt Zeiher

Since Specialization

Citations

This map shows the geographic impact of Bernhardt Zeiher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bernhardt Zeiher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bernhardt Zeiher more than expected).

Fields of papers citing papers by Bernhardt Zeiher

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bernhardt Zeiher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bernhardt Zeiher. The network helps show where Bernhardt Zeiher may publish in the future.

Co-authorship network of co-authors of Bernhardt Zeiher

This figure shows the co-authorship network connecting the top 25 collaborators of Bernhardt Zeiher. A scholar is included among the top collaborators of Bernhardt Zeiher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bernhardt Zeiher. Bernhardt Zeiher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Delgado‐Herrera, Leticia, Kathryn Lasch, Bernhardt Zeiher, et al.. (2017). Evaluation and performance of a newly developed patient-reported outcome instrument for diarrhea-predominant irritable bowel syndrome in a clinical study population. Therapeutic Advances in Gastroenterology. 10(9). 673–687. 4 indexed citations

Delgado‐Herrera, Leticia, et al.. (2017). Diarrhea-predominant irritable bowel syndrome: creation of an electronic version of a patient-reported outcome instrument by conversion from a pen-and-paper version and evaluation of their equivalence. SHILAP Revista de lepidopterología. Volume 8. 83–95. 4 indexed citations

Delgado‐Herrera, Leticia, et al.. (2016). Cultural adaptation: translatability assessment and linguistic validation of the patient-reported outcome instrument for irritable bowel syndrome with diarrhea. SHILAP Revista de lepidopterología. 7. 81–81. 2 indexed citations

Maertens, Johan, Thomas F. Patterson, Galia Rahav, et al.. (2015). Phase 3 Randomized, Double-Blind Trial Evaluating Isavuconazole vs. Voriconazole for Primary Treatment of Invasive Fungal Disease Caused by Aspergillus Spp. or Other Filamentous Fungi (SECURE). Mycoses. 58. 196–196. 4 indexed citations

Marquis, Patrick, Kathryn Lasch, Leticia Delgado‐Herrera, et al.. (2014). Qualitative Development of a Patient-Reported Outcome Symptom Measure in Diarrhea-Predominant Irritable Bowel Syndrome. Clinical and Translational Gastroenterology. 5(6). e59–e59. 14 indexed citations

Marty, Francisco M., John R. Perfect, Oliver A. Cornely, et al.. (2014). 824An Open-Label Phase 3 Study of Isavuconazole (VITAL): Focus on Mucormycosis. Open Forum Infectious Diseases. 1(suppl_1). S235–S236. 21 indexed citations

Pauer, L., Gary Atkinson, T.K. Murphy, Danielle Petersel, & Bernhardt Zeiher. (2012). Long-term Maintenance of Response Across Multiple Fibromyalgia Symptom Domains in a Randomized Withdrawal Study of Pregabalin. Clinical Journal of Pain. 28(7). 609–614. 11 indexed citations

Arnold, Lesley M., Birol Emir, T.K. Murphy, et al.. (2012). Safety Profile and Tolerability of Up to 1 Year of Pregabalin Treatment in 3 Open-Label Extension Studies in Patients With Fibromyalgia. Clinical Therapeutics. 34(5). 1092–1102. 21 indexed citations

Fleishaker, Dona, Xin Wang, Sujatha Menon, et al.. (2012). Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial. Arthritis Research & Therapy. 14(1). R11–R11. 51 indexed citations

10.

Pauer, L., Andreas Winkelmann, Pierre Arsenault, et al.. (2011). An International, Randomized, Double-blind, Placebo-controlled, Phase III Trial of Pregabalin Monotherapy in Treatment of Patients with Fibromyalgia. The Journal of Rheumatology. 38(12). 2643–2652. 70 indexed citations

11.

Murphy, Kevin, et al.. (2009). Long-term safety and tolerability of pregabalin treatment in three open-label extension studies in patients with fibromyalgia. Journal of Pain. 10(4). S58–S58. 3 indexed citations

12.

Brandt, John T., et al.. (2006). Urinary desmosine as a biomarker in acute lung injury. Biomarkers. 11(1). 85–96. 10 indexed citations

13.

Bowton, David L., Alexei Dmitrienko, Elliot Israel, Bernhardt Zeiher, & Gregory D. Sides. (2005). Impact of a Soluble Phospholipase A₂Inhibitor on Inhaled Allergen Challenge in Subjects with Asthma. Journal of Asthma. 42(1). 65–71. 33 indexed citations

14.

Zeiher, Bernhardt, et al.. (2005). LY315920NA/S-5920, a selective inhibitor of group IIA secretory phospholipase A2, fails to improve clinical outcome for patients with severe sepsis*. Critical Care Medicine. 33(8). 1741–1748. 87 indexed citations

15.

Zeiher, Bernhardt, Antonio Artigas, Jean‐Louis Vincent, et al.. (2004). Neutrophil elastase inhibition in acute lung injury: Results of the STRIVE study. Critical Care Medicine. 32(8). 1695–1702. 246 indexed citations

16.

Zeiher, Bernhardt, Shozo Matsuoka, Kazuhito Kawabata, & John E. Repine. (2002). Neutrophil elastase and acute lung injury: Prospects for sivelestat and other neutrophil elastase inhibitors as therapeutics. Critical Care Medicine. 30(Supplement). S281–S287. 103 indexed citations

17.

Zeiher, Bernhardt & Douglas B. Hornick. (1996). Pathogenesis of respiratory infections and host defenses. Current Opinion in Pulmonary Medicine. 2(3). 166–173. 18 indexed citations

18.

Zeiher, Bernhardt, E. J. Eichwald, Joseph Zabner, et al.. (1995). A mouse model for the delta F508 allele of cystic fibrosis.. Journal of Clinical Investigation. 96(4). 2051–2064. 249 indexed citations breakdown →

19.

Zeiher, Bernhardt, Thomas Groß, Jeffrey A. Kern, Louis A. Lanza, & Michael W. Peterson. (1995). Predicting Postoperative Pulmonary Function in Patients Undergoing Lung Resection. CHEST Journal. 108(1). 68–72. 119 indexed citations

20.

Snyder, Peter M., Margaret P. Price, Fiona J. McDonald, et al.. (1995). Mechanism by which Liddle's syndrome mutations increase activity of a human epithelial Na+ channel. Cell. 83(6). 969–978. 333 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact